6 Parkinson’s Biotech Companies: Where Are They in 2021?
XTalks
APRIL 12, 2021
Like other neurodegenerative disorders, such as Alzheimer’s disease and dementias, Parkinson’s disease research has been immensely challenging for biotechs, with a high rate of late-stage attrition in trials leading to a lack of disease-modifying therapies being approved. Cellular accumulation of ?-synuclein
Let's personalize your content